Related Experiment Videos
[Phenoxybenzamine in prostatic pathology. 300 cases (author's transl)]
Journal D'Urologie
|January 1, 1981
Summary
Alpha-blocker therapy, specifically phenoxybenzamine, effectively treats prostatic symptoms, improving outcomes in dysuria and urinary retention. This treatment can delay or prevent surgery, aiding pre- and post-operative care in 300 cases.
Area of Science:
- Urology
- Pharmacology
Context:
- Benign prostatic hyperplasia (BPH) management.
- Limitations of existing BPH treatments.
Purpose:
- Evaluate the efficacy of alpha-blockers in treating prostatic symptoms.
- Assess the impact of phenoxybenzamine on surgical intervention for BPH.
Summary:
- Phenoxybenzamine, an alpha-blocker, demonstrated significant efficacy in managing prostatic symptoms over four years.
- Remarkable improvements were observed in patients experiencing dysuria and acute urinary retention.
- Therapy facilitated pre- and post-operative phases, delaying or avoiding surgery in a substantial number of cases (300 patients).
Impact:
- Alpha-blocker therapy offers a viable, effective alternative to surgery for certain BPH patients.
- Improved patient outcomes and quality of life through symptom management.
- Potential to reduce healthcare costs associated with surgical interventions for BPH.